The IPI was published in 1993 and remains the main prognostic tool in aggressive lymphoma. The revised IPI uses the same five factors but regroups them for the rituximab era.
How to use the IPI Calculator
- Age over 60
- Ann Arbor stage III or IV
- Serum LDH above the upper limit of normal
- ECOG performance status 2 or more
- More than one extranodal site
Results update as you type, and every field accepts the units shown in its menu.
How it works
Each answer carries the points shown in the published score. The calculator adds them up and maps the total to the published interpretation.
Scoring table
| Item | Answers and points |
|---|---|
| Age over 60 | No = 0; Yes = 1 |
| Ann Arbor stage III or IV | No = 0; Yes = 1 |
| Serum LDH above the upper limit of normal | No = 0; Yes = 1 |
| ECOG performance status 2 or more | No = 0; Yes = 1 |
| More than one extranodal site | No = 0; Yes = 1 |
Inputs explained
| Field | What to enter |
|---|---|
| Age over 60 | Choose one: No, Yes |
| Ann Arbor stage III or IV | Choose one: No, Yes |
| Serum LDH above the upper limit of normal | Choose one: No, Yes |
| ECOG performance status 2 or more | Choose one: No, Yes |
| More than one extranodal site | Choose one: No, Yes |
Health note: this calculator is for education and screening only and is not a diagnosis or treatment advice. Discuss your results with a qualified clinician.
Formula
Score = sum of the points for each item
Worked example
Inputs — Age over 60: Yes; Ann Arbor stage III or IV: No; Serum LDH above the upper limit of normal: Yes; ECOG performance status 2 or more: No; More than one extranodal site: No.
Results — IPI score = 2 / 5; IPI risk group = Low-intermediate; Revised IPI (R-CHOP era) = Good (about 79%).
Key terms
- DLBCL
- Diffuse large B-cell lymphoma.
- ECOG
- Eastern Cooperative Oncology Group performance status.
Frequently asked questions
What is a good IPI score?
0–1.
What is the NCCN-IPI?
A refined version that weights age and LDH more finely.
Does the IPI guide treatment?
It informs prognosis and clinical trial eligibility rather than standard first-line treatment.